Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston starts drug-eluting stent trial enrolment:

This article was originally published in Clinica

Executive Summary

Boston Scientific (Massachusetts, US) has begun the enrolment phase of its 532-patient, international study to assess its drug-eluting stent. The TAXUS II trial, which is being led by cardiologist Antonio Colombo, of EMO Centro Cuore Colombus, Milan, Italy, will investigate the use of Boston's paclitaxel-eluting stent technology as a means of preventing restenosis. Data from the trial will be used to support an application to market the product in Europe and in other international markets, the firm says.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT072082

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel